Comparative Pharmacology
Head-to-head clinical analysis: CEFPODOXIME PROXETIL versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPODOXIME PROXETIL versus DURICEF.
CEFPODOXIME PROXETIL vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpodoxime proxetil is a prodrug that is de-esterified in vivo to cefpodoxime, a third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and disrupting peptidoglycan cross-linking, leading to cell lysis. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
200 mg orally every 12 hours
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
Terminal elimination half-life of cefpodoxime is 2.2-2.8 hours in healthy adults; prolonged to 5.9-9.8 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 13-14 hours in severe impairment (CrCl <10 mL/min).
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Renal excretion of unchanged drug (29-33%) and fecal/biliary elimination of inactive metabolites; 80% of radiolabeled dose recovered in urine and feces over 8 days.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic